Reynolds Matthew W, Clark John, Crean Sheila, Samudrala Srinath
Epidemiology and Database Services, United BioSource Corporation, Medford, MA, USA.
Patient Saf Surg. 2008 Mar 18;2:5. doi: 10.1186/1754-9493-2-5.
One of the most anticipated, but potentially serious complications during or after surgery are bleeding events. Among the many potential factors associated with bleeding complications in surgery, the use of bovine thrombin has been anecdotally identified as a possible cause of increased bleeding risk. Most of these reports of bleeding events in association with the use of topical bovine thrombin have been limited to case reports lacking clear cause and effect relationship determination. Recent studies have failed to establish significant differences in the rates of bleeding events between those treated with bovine thrombin and those treated with either human or recombinant thrombin.
We conducted a search of MEDLINE for the most recent past 10 years (1997-2007) and identified all published studies that reported a study of surgical patients with a clear objective to examine the risk of bleeding events in surgical patients. We also specifically noted the reporting of any topical bovine thrombin used during surgical procedures. We aimed to examine whether there were any differences in the risk of bleeds in general surgical populations as compared to those studies that reported exposure to topical bovine thrombin.
We identified 21 clinical studies that addressed the risk of bleeding in surgery. Of these, 5 studies analyzed the use of bovine thrombin sealants in surgical patients. There were no standardized definitions for bleeding events employed across these studies. The rates of bleeds in the general surgery studies ranged from 0.1%-20.2%, with most studies reporting rates between 2.6%-4%. The rates of bleeding events ranged from 0.0%-13% in the bovine thrombin studies with most studies reporting between a 2%-3% rate.
The risk of bleeds was not clearly different in those studies reporting use of bovine thrombin in all patients compared to the other surgical populations studied. A well-designed and well-controlled study is needed to accurately examine the bleeding risks in surgical patients treated and unexposed to topical bovine thrombin, and to evaluate the independent risk associated with topical bovine thrombin as well as other risk factors.
手术期间或术后最令人担忧但可能严重的并发症之一是出血事件。在与手术出血并发症相关的众多潜在因素中,牛凝血酶的使用一直被传闻是出血风险增加的可能原因。大多数与局部使用牛凝血酶相关的出血事件报告仅限于缺乏明确因果关系判定的病例报告。最近的研究未能确定使用牛凝血酶治疗的患者与使用人凝血酶或重组凝血酶治疗的患者在出血事件发生率上存在显著差异。
我们检索了MEDLINE过去10年(1997 - 2007年)的文献,确定了所有已发表的研究,这些研究报告了对手术患者进行的研究,其明确目的是检查手术患者的出血事件风险。我们还特别注意了手术过程中使用任何局部牛凝血酶的报告情况。我们旨在研究普通外科人群的出血风险与那些报告接触局部牛凝血酶的研究相比是否存在差异。
我们确定了21项涉及手术出血风险的临床研究。其中,5项研究分析了牛凝血酶密封剂在手术患者中的使用情况。这些研究中对出血事件没有采用标准化定义。普通外科研究中的出血率在0.1% - 20.2%之间,大多数研究报告的出血率在2.6% - 4%之间。牛凝血酶研究中的出血事件发生率在0.0% - 13%之间,大多数研究报告的发生率在2% - 3%之间。
与其他研究的手术人群相比,在所有患者中报告使用牛凝血酶的那些研究中,出血风险没有明显差异。需要进行一项设计良好且控制严格的研究,以准确检查接受和未接受局部牛凝血酶治疗的手术患者的出血风险,并评估与局部牛凝血酶以及其他风险因素相关的独立风险。